21 July 2026

Results of Share Purchase Plan

Control Bionics Limited (ASX: CBL) is pleased to announce the completion of its Share Purchase Plan (**SPP**) following the closing of applications on 14 July 2026.

The SPP received applications totalling $256,500.

The amount raised under the SPP brought the total amount raised including the recent placement to $9.75m. Of this amount $6.1m was raised from new investors and existing shareholders contributed $3.65m.

Tranche 1 of the placement of $2.25 million was received on 30 June 2026 and Tranche 2 of the placement of $7.25 million will be funded subject to shareholder approval being received at the General Meeting on 6 August 2026.

The Board extends its sincere thanks to shareholders for their ongoing support as Control Bionics continues to deliver on its strategic objectives.

In accordance with the terms of the SPP, the issue price of new fully paid ordinary shares (**New Shares)** under the SPP is 7.5c.

A total of 3,419,993 New Shares will be issued today and trading of the New Shares on the ASX is expected to commence tomorrow.

This announcement has been authorised for release by Control Bionics Chairman, Stephen Rix.

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

CONTROL BIONICS

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes.

A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.